Ono Pharmaceutical Co., Ltd. Logo

Ono Pharmaceutical Co., Ltd.

OPHLY

(3.0)
Stock Price

3,43 USD

18.02% ROA

12% ROE

2.59x PER

Market Cap.

939.865.763.600,14 USD

19.7% DER

0% Yield

19.64% NPM

Ono Pharmaceutical Co., Ltd. Stock Analysis

Ono Pharmaceutical Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ono Pharmaceutical Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (16.21%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

5 PBV

The stock's PBV ratio (1.94x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

7 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

8 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (4.173) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Ono Pharmaceutical Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ono Pharmaceutical Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Ono Pharmaceutical Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ono Pharmaceutical Co., Ltd. Revenue
Year Revenue Growth
2005 145.302.000.000
2006 148.671.000.000 2.27%
2007 141.711.000.000 -4.91%
2008 145.897.000.000 2.87%
2009 136.556.000.000 -6.84%
2010 135.986.000.000 -0.42%
2011 135.255.000.000 -0.54%
2012 145.778.000.000 7.22%
2013 145.393.000.000 -0.26%
2014 143.247.000.000 -1.5%
2015 135.775.000.000 -5.5%
2016 160.284.000.000 15.29%
2017 244.797.000.000 34.52%
2018 261.836.000.000 6.51%
2019 288.634.000.000 9.28%
2020 292.420.000.000 1.29%
2021 309.284.000.000 5.45%
2022 361.361.000.000 14.41%
2023 554.788.000.000 34.87%
2023 447.187.000.000 -24.06%
2024 502.672.000.000 11.04%
2025 470.700.000.000 -6.79%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ono Pharmaceutical Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 44.763.000.000 100%
2014 44.413.000.000 -0.79%
2015 41.346.000.000 -7.42%
2016 43.369.000.000 4.66%
2017 57.506.000.000 24.58%
2018 68.821.000.000 16.44%
2019 70.008.000.000 1.7%
2020 66.497.000.000 -5.28%
2021 62.384.000.000 -6.59%
2022 75.879.000.000 17.78%
2023 99.124.000.000 23.45%
2023 95.344.000.000 -3.96%
2024 112.174.000.000 15%
2025 115.428.000.000 2.82%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ono Pharmaceutical Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 53.393.000.000
2006 58.169.000.000 8.21%
2007 57.883.000.000 -0.49%
2008 61.785.000.000 6.32%
2009 62.932.000.000 1.82%
2010 64.754.000.000 2.81%
2011 65.241.000.000 0.75%
2012 67.493.000.000 3.34%
2013 70.801.000.000 4.67%
2014 38.381.000.000 -84.47%
2015 42.222.000.000 9.1%
2016 43.979.000.000 4%
2017 62.049.000.000 29.12%
2018 68.055.000.000 8.83%
2019 70.033.000.000 2.82%
2020 67.679.000.000 -3.48%
2021 69.230.000.000 2.24%
2022 77.057.000.000 10.16%
2023 96.484.000.000 20.13%
2023 89.486.000.000 -7.82%
2024 100.270.000.000 10.75%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ono Pharmaceutical Co., Ltd. EBITDA
Year EBITDA Growth
2005 66.321.000.000
2006 63.286.000.000 -4.8%
2007 60.129.000.000 -5.25%
2008 58.488.000.000 -2.81%
2009 49.757.000.000 -17.55%
2010 45.723.000.000 -8.82%
2011 40.591.000.000 -12.64%
2012 43.458.000.000 6.6%
2013 36.848.000.000 -17.94%
2014 34.643.000.000 -6.36%
2015 24.472.000.000 -41.56%
2016 40.097.000.000 38.97%
2017 82.621.000.000 51.47%
2018 73.171.000.000 -12.91%
2019 75.912.000.000 3.61%
2020 94.755.000.000 19.89%
2021 116.847.000.000 18.91%
2022 123.620.000.000 5.48%
2023 245.976.000.000 49.74%
2023 161.896.000.000 -51.93%
2024 181.242.000.000 10.67%
2025 140.272.000.000 -29.21%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ono Pharmaceutical Co., Ltd. Gross Profit
Year Gross Profit Growth
2005 124.288.000.000
2006 126.856.000.000 2.02%
2007 120.626.000.000 -5.16%
2008 125.036.000.000 3.53%
2009 115.238.000.000 -8.5%
2010 115.149.000.000 -0.08%
2011 110.496.000.000 -4.21%
2012 116.792.000.000 5.39%
2013 111.410.000.000 -4.83%
2014 110.500.000.000 -0.82%
2015 100.639.000.000 -9.8%
2016 118.760.000.000 15.26%
2017 179.273.000.000 33.75%
2018 196.445.000.000 8.74%
2019 204.805.000.000 4.08%
2020 213.357.000.000 4.01%
2021 223.711.000.000 4.63%
2022 267.850.000.000 16.48%
2023 416.412.000.000 35.68%
2023 337.125.000.000 -23.52%
2024 375.546.000.000 10.23%
2025 352.016.000.000 -6.68%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ono Pharmaceutical Co., Ltd. Net Profit
Year Net Profit Growth
2005 39.322.000.000
2006 36.146.000.000 -8.79%
2007 35.271.000.000 -2.48%
2008 35.046.000.000 -0.64%
2009 23.766.000.000 -47.46%
2010 27.878.000.000 14.75%
2011 24.222.000.000 -15.09%
2012 24.360.000.000 0.57%
2013 22.919.000.000 -6.29%
2014 20.344.000.000 -12.66%
2015 12.976.000.000 -56.78%
2016 24.979.000.000 48.05%
2017 55.793.000.000 55.23%
2018 50.284.000.000 -10.96%
2019 51.539.000.000 2.44%
2020 59.704.000.000 13.68%
2021 75.425.000.000 20.84%
2022 80.519.000.000 6.33%
2023 170.692.000.000 52.83%
2023 112.723.000.000 -51.43%
2024 127.977.000.000 11.92%
2025 99.176.000.000 -29.04%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ono Pharmaceutical Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 22
2006 20 -10%
2007 20 0%
2008 20 0%
2009 14 -42.86%
2010 17 17.65%
2011 15 -21.43%
2012 15 6.67%
2013 14 -7.14%
2014 3 -600%
2015 2 -100%
2016 16 93.33%
2017 35 57.14%
2018 32 -9.38%
2019 33 3.03%
2020 39 15.38%
2021 50 22%
2022 54 7.41%
2023 118 53.85%
2023 77 -53.95%
2024 89 13.64%
2025 211 58.29%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ono Pharmaceutical Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2005 26.081.000.000
2006 38.754.000.000 32.7%
2007 37.547.000.000 -3.21%
2008 34.929.000.000 -7.5%
2009 23.017.000.000 -51.75%
2010 18.090.000.000 -27.24%
2011 28.502.000.000 36.53%
2012 19.611.000.000 -45.34%
2013 11.084.000.000 -76.93%
2014 15.565.000.000 28.79%
2015 461.000.000 -3276.36%
2016 -1.240.000.000 137.18%
2017 50.371.000.000 102.46%
2018 -14.111.000.000 456.96%
2019 37.172.000.000 137.96%
2020 51.712.000.000 28.12%
2021 53.684.000.000 3.67%
2022 49.552.000.000 -8.34%
2023 45.210.000.000 -9.6%
2023 145.113.000.000 68.84%
2024 89.831.000.000 -61.54%
2025 -731.000.000 12388.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ono Pharmaceutical Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2005 28.850.000.000
2006 39.928.000.000 27.74%
2007 38.678.000.000 -3.23%
2008 36.521.000.000 -5.91%
2009 24.525.000.000 -48.91%
2010 21.301.000.000 -15.14%
2011 29.796.000.000 28.51%
2012 21.634.000.000 -37.73%
2013 15.661.000.000 -38.14%
2014 28.422.000.000 44.9%
2015 31.579.000.000 10%
2016 12.842.000.000 -145.9%
2017 74.450.000.000 82.75%
2018 15.727.000.000 -373.39%
2019 66.774.000.000 76.45%
2020 74.157.000.000 9.96%
2021 73.977.000.000 -0.24%
2022 61.829.000.000 -19.65%
2023 46.359.000.000 -33.37%
2023 159.610.000.000 70.95%
2024 110.660.000.000 -44.23%
2025 813.000.000 -13511.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ono Pharmaceutical Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2005 2.769.000.000
2006 1.174.000.000 -135.86%
2007 1.131.000.000 -3.8%
2008 1.592.000.000 28.96%
2009 1.508.000.000 -5.57%
2010 3.211.000.000 53.04%
2011 1.294.000.000 -148.15%
2012 2.023.000.000 36.04%
2013 4.577.000.000 55.8%
2014 12.857.000.000 64.4%
2015 31.118.000.000 58.68%
2016 14.082.000.000 -120.98%
2017 24.079.000.000 41.52%
2018 29.838.000.000 19.3%
2019 29.602.000.000 -0.8%
2020 22.445.000.000 -31.89%
2021 20.293.000.000 -10.6%
2022 12.277.000.000 -65.29%
2023 1.149.000.000 -968.49%
2023 14.497.000.000 92.07%
2024 20.829.000.000 30.4%
2025 1.544.000.000 -1249.03%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ono Pharmaceutical Co., Ltd. Equity
Year Equity Growth
2005 391.430.000.000
2006 443.631.000.000 11.77%
2007 446.805.000.000 0.71%
2008 430.263.000.000 -3.84%
2009 390.041.000.000 -10.31%
2010 406.109.000.000 3.96%
2011 394.572.000.000 -2.92%
2012 400.968.000.000 1.6%
2013 423.289.000.000 5.27%
2014 451.996.000.000 6.35%
2015 475.213.000.000 4.89%
2016 476.255.000.000 0.22%
2017 524.211.000.000 9.15%
2018 529.618.000.000 1.02%
2019 562.736.000.000 5.89%
2020 568.022.000.000 0.93%
2021 641.157.000.000 11.41%
2022 661.674.000.000 3.1%
2023 783.288.000.000 15.53%
2023 747.813.000.000 -4.74%
2024 798.605.000.000 6.36%
2025 816.413.000.000 2.18%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ono Pharmaceutical Co., Ltd. Assets
Year Assets Growth
2005 439.274.000.000
2006 504.446.000.000 12.92%
2007 504.814.000.000 0.07%
2008 477.341.000.000 -5.76%
2009 421.280.000.000 -13.31%
2010 433.226.000.000 2.76%
2011 424.442.000.000 -2.07%
2012 436.413.000.000 2.74%
2013 455.571.000.000 4.21%
2014 485.962.000.000 6.25%
2015 524.588.000.000 7.36%
2016 540.450.000.000 2.93%
2017 617.461.000.000 12.47%
2018 609.226.000.000 -1.35%
2019 655.056.000.000 7%
2020 673.444.000.000 2.73%
2021 746.842.000.000 9.83%
2022 739.203.000.000 -1.03%
2023 895.918.000.000 17.49%
2023 882.437.000.000 -1.53%
2024 913.668.000.000 3.42%
2025 1.083.697.000.000 15.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ono Pharmaceutical Co., Ltd. Liabilities
Year Liabilities Growth
2005 47.844.000.000
2006 60.815.000.000 21.33%
2007 58.009.000.000 -4.84%
2008 47.078.000.000 -23.22%
2009 31.239.000.000 -50.7%
2010 27.117.000.000 -15.2%
2011 29.870.000.000 9.22%
2012 35.445.000.000 15.73%
2013 32.282.000.000 -9.8%
2014 33.966.000.000 4.96%
2015 49.375.000.000 31.21%
2016 64.195.000.000 23.09%
2017 93.250.000.000 31.16%
2018 79.608.000.000 -17.14%
2019 92.320.000.000 13.77%
2020 105.422.000.000 12.43%
2021 105.685.000.000 0.25%
2022 77.529.000.000 -36.32%
2023 112.630.000.000 31.16%
2023 134.624.000.000 16.34%
2024 115.063.000.000 -17%
2025 267.284.000.000 56.95%

Ono Pharmaceutical Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1064.47
Net Income per Share
257.33
Price to Earning Ratio
2.59x
Price To Sales Ratio
1.88x
POCF Ratio
2.59
PFCF Ratio
8.83
Price to Book Ratio
0.39
EV to Sales
1.93
EV Over EBITDA
5.57
EV to Operating CashFlow
7.97
EV to FreeCashFlow
9.07
Earnings Yield
0.39
FreeCashFlow Yield
0.11
Market Cap
939,87 Bil.
Enterprise Value
965,34 Bil.
Graham Number
3160.18
Graham NetNet
49.02

Income Statement Metrics

Net Income per Share
257.33
Income Quality
0.82
ROE
0.15
Return On Assets
0.09
Return On Capital Employed
0.13
Net Income per EBT
0.8
EBT Per Ebit
0.98
Ebit per Revenue
0.25
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0.15
Research & Developement to Revenue
0.23
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.75
Operating Profit Margin
0.25
Pretax Profit Margin
0.25
Net Profit Margin
0.2

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.31
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
257.67
Free CashFlow per Share
226.54
Capex to Operating CashFlow
0.12
Capex to Revenue
0.03
Capex to Depreciation
0.81
Return on Invested Capital
0.12
Return on Tangible Assets
0.18
Days Sales Outstanding
109.69
Days Payables Outstanding
174.92
Days of Inventory on Hand
153.59
Receivables Turnover
3.33
Payables Turnover
2.09
Inventory Turnover
2.38
Capex per Share
31.13

Balance Sheet

Cash per Share
321,08
Book Value per Share
1.736,94
Tangible Book Value per Share
859.63
Shareholders Equity per Share
1724.86
Interest Debt per Share
342.36
Debt to Equity
0.2
Debt to Assets
0.15
Net Debt to EBITDA
0.15
Current Ratio
1.53
Tangible Asset Value
404,05 Bil.
Net Current Asset Value
120,00 Bil.
Invested Capital
655579000000
Working Capital
134,54 Bil.
Intangibles to Total Assets
0.38
Average Receivables
143,21 Bil.
Average Payables
60,69 Bil.
Average Inventory
50955500000
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ono Pharmaceutical Co., Ltd. Dividends
Year Dividends Growth
2012 1
2013 2 0%
2014 1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Ono Pharmaceutical Co., Ltd. Profile

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

CEO
Mr. Gyo Sagara
Employee
4.258
Address
8-2, Kyutaromachi 1-chome
Osaka, 541-8564

Ono Pharmaceutical Co., Ltd. Executives & BODs

Ono Pharmaceutical Co., Ltd. Executives & BODs
# Name Age
1 Takehiro Yamada
Corporate Officer & Head of Risk and Compliance Management Department
70
2 Satoshi Takahagi
Corporate Executive Off. and Exe. Dir. of Sales, Marketing & Oncology Business Division
70
3 Masayuki Tanigawa
Corporate Officer & Head of Business Strategy Headquarters
70
4 Hiromu Habashita Ph.D.
Corporate Officer & Deputy Executive Director, Discovery & Research
70
5 Mr. Gyo Sagara
Chief Executive Officer & Chairman of the Board
70
6 Mr. Masaki Ito
Corporation Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., and Corp. Tax
70
7 Mr. Toshihiro Tsujinaka
Ex. EO, Exe. Dir. of Sus. Promotion Corporation Strategy, Planning & HR Divi. and Representative Dir.
70
8 Akira Takada
Corporate Executive Officer, Executive Director, CMC & Production, Production Technology Management
70
9 Mr. Toichi Takino Ph.D.
President, Chief Operating Officer & Representative Director
70
10 Shinji Takai M.D., Ph.D.
Corporate Officer & Head of Medical Affairs
70

Ono Pharmaceutical Co., Ltd. Competitors

GSK plc Logo
GSK plc

GLAXF

(1.8)
Grifols, S.A. Logo
Grifols, S.A.

GRFS

(0.5)
Pfizer Inc. Logo
Pfizer Inc.

PFE

(2.5)
Sanofi Logo
Sanofi

SNY

(3.0)
Organon & Co. Logo
Organon & Co.

OGN

(2.2)
GSK plc Logo
GSK plc

GSK

(2.2)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)
Roche Holding AG Logo
Roche Holding AG

RHHBY

(2.5)
Novartis AG Logo
Novartis AG

NVS

(2.0)
Merck & Co., Inc. Logo
Merck & Co., Inc.

MRK

(2.2)
Amgen Inc. Logo
Amgen Inc.

AMGN

(3.2)
Johnson & Johnson Logo
Johnson & Johnson

JNJ

(2.8)
AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)